Edition:
United States

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

2.77USD
19 Apr 2018
Change (% chg)

$-0.04 (-1.42%)
Prev Close
$2.81
Open
$2.77
Day's High
$2.77
Day's Low
$2.77
Volume
1,120
Avg. Vol
8,248
52-wk High
$5.46
52-wk Low
$0.34

Select another date:

Thu, Mar 29 2018

BRIEF-Citius Announces $2 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co

* CITIUS PHARMACEUTICALS INC - ‍ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017​ Source text: (http://bit.ly/2iwTNyZ) Further company coverage:

BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing‍​

* Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing‍​ Source text: (http://bit.ly/2zKcjdY) Further company coverage:

BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial

* Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Select another date: